Back to Authors

Wang, Y.

A5020646692 | I4210125099

Mayo Clinic in Arizona

Citations 17

PIRTOBRUTINIB IN COVALENT BTK‐INHIBITOR PRE‐TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS, SUBGROUP ANALYSIS FROM BRUIN WITH >3 YEARS FOLLOW‐UP FROM START OF ENROLLMENT

Hematological Oncology | June 9, 2023 | Volume: 41 | Issue: S2 | Pages: 153-156

10.1002/hon.3163_102

P1155: BREXUCABTAGENE AUTOLEUCEL FOR RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA IN ROUTINE PRACTICE: UPDATED REPORT FROM THE US LYMPHOMA CAR T CONSORTIUM

HemaSphere | June 23, 2022 | Volume: 6 | Issue: No issue available | Pages: 1042-1043

10.1097/01.hs9.0000847488.86807.da

P1094: CHARACTERISTICS, MANAGEMENT, AND OUTCOMES OF PATIENTS WITH T-CELL LARGE GRANULAR LYMPHOCYTIC LEUKEMIA AT A LARGE TERTIARY CARE CENTER

HemaSphere | June 23, 2022 | Volume: 6 | Issue: No issue available | Pages: 984-985

10.1097/01.hs9.0000847244.78761.0a

P1100: BRUIN MCL-321: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB VS INVESTIGATOR CHOICE OF BTK INHIBITOR IN PATIENTS WITH PREVIOUSLY TREATED, BTK INHIBITOR NAÏVE MCL (TRIAL IN PROGRESS)

HemaSphere | June 23, 2022 | Volume: 6 | Issue: No issue available | Pages: 990-991

10.1097/01.hs9.0000847268.67095.fc

P1101: PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN PREVIOUSLY TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS FROM THE PHASE 1/2 BRUIN STUDY

HemaSphere | June 23, 2022 | Volume: 6 | Issue: No issue available | Pages: 991-992

10.1097/01.hs9.0000847272.47630.ff

P656: INCIDENT VENOUS THROMBOEMBOLISM (VTE) IN PATIENTS WITH MONOCLONAL B-CELL LYMPHOCYTOSIS (MBL) AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) – A POPULATION-BASED STUDY

HemaSphere | June 23, 2022 | Volume: 6 | Issue: No issue available | Pages: 554-555

10.1097/01.hs9.0000845508.29001.67

HOST GENETIC VARIATION IN THE TNF AND NF‐ĸB PATHWAYS AND PROGNOSIS IN MANTLE CELL LYMPHOMA: AN ANALYSIS OF 2 STUDIES

Hematological Oncology | June 7, 2017 | Volume: 35 | Issue: S2 | Pages: 151-152

10.1002/hon.2438_4